New Data in NSCLC Bolster Support for Perioperative Immunotherapy
CHICAGO — A randomized trial testing the addition of perioperative pembrolizumab (Keytruda) to chemotherapy in operable non-small cell lung cancer (NSCLC) hit one of its two primary endpoints in an interim analysis, with a favorable trend for the other. All patients in the study received cisplatin-based neoadjuvant chemotherapy, and at 2 years, the event-free survival […]
Taxane, Anthracycline Combo Most Effective in Reducing Breast Cancer Recurrence
Combining anthracycline and taxane for early-stage operable breast cancer was more effective than either anthracycline or taxane chemotherapy alone in reducing breast cancer recurrence and death, according to a meta-analysis. Moreover, regimens with higher cumulative doses of anthracycline plus taxane were associated with the greatest benefit, according to a report from Jeremy Braybrooke, BM, PhD, […]